Iqsoft Guarantees Satisfaction

Or Your Money back !!!

Ask for a quote
Drug ISRIB is a Memory Enhancer, Anti Cancer Agent, Protects Hearing and Perhaps has anti Aging Effects

Aging Mice Have Memory And Cognitive Declines Reversed With An Experimental Drug

Rebecca Coffey

 

A small-molecule drug named ISRIB quickly and safely restores to old mice youthful levels of cognitive function. Alphabet Inc,’s Biotech Firm Calico holds the license to ISRIB.


 

The anti-aging properties of ISRIB (pronounced “iz-rib”) were discovered in a collaboration between neurocognitive researcher Susanna Rosi and biochemist and biophysicist Peter Walter, both of the University of California, San Francisco. In a previous project Rosi and Walter showed that ISRIB could reverse memory failure and restore normal cognitive function in mice after traumatic brain injury — and it could do so even when it was given to the mice weeks after the injury. Prior to his work with Rosi, Walter and other collaborators demonstrated that ISRIB enhances memory in healthy mice and in mice with Down syndrome, and causes some treatment-resistant prostate cancer cells to self-destruct. Other research teams working with ISRIB have shown it to protect mice’s inner ears against noise-related hearing loss.

 
Dr. .Susanna Rosi

Dr. Susanna Rosi

SUSAN MERRELL, COURTESY UCSF

In all studies, the researchers have observed no serious side effects.

 The new study on the reverse of age-related cognitive decline was published on December 1 in the journal eLife. According to the eLife paper, ISRIB rejuvenates brain cells and cognitive function by interfering with the Integrated Stress Response (ISR), which is a set of signaling pathways in the brain that call key protective processes into action.

Proteins do much of the work throughout the body and brain, and so healthy cells constantly create them. When injury, infection, or mutation create problems for cells, the ISR slows down their protein production greatly. This gives the cells time to heal. As helpful as that safety response is, in the brain it has its costs. Both memory and learning depend on active protein production. When the ISR blocks production, both suffer — sometimes so profoundly and for so long that the cognitive deficits can seem permanent.

As Rosi explained in a Zoom interview, “One way to think of how ISRIB rejuvenates brain cells and cognitive function is that, when the ISR protectively blocks production of proteins, it’s as though it’s setting a switch to ‘off.’ Ideally, that would be a temporary change only. What we’re learning from our work is that sometimes the ISR gets ‘stuck’ and doesn’t let the switch move back to ‘on.’ That can make the cognitive deficits that were caused by the ISR itself seem to be a result of permanent damage — when they’re not.”

In turning the protein production switch back to “on,” ISRIB activates a specific enzyme that the ISR had blocked. Re-activated, that enzyme triggers resumption of normal protein production.

Dr. Peter Walter

Dr. Peter Walter

STEVE BABULJAK, COURTESY UCSF

The lab experiments central to Rosi and Walter’s demonstration of rejuvenation in the brain cells and cognitive function of old mice were led by Karen Krukowski, a research physical therapist with a special interest in the impact of aging and traumatic brain injury on cognitive decline. In a test of the mice’s spatial memory and ability to learn, for two days Krukowski’s team trained mice to escape from a maze. The task required finding a platform hidden under water that had been made opaque. Young mice typically required only two tries to escape the maze. Old mice that weren’t treated with ISRIB typically required four tries. On average, old mice given a few daily doses of ISRIB required only three tries.

To specifically test spatial memory, one week later the experimenters had old and young mice escape the same opaque water maze as before. The mice did not receive any additional training or ISRIB treatment for this test. The old mice that had originally been treated with ISRIB remembered about as well as young mice how to escape the maze. The untreated old mice did not.

To test episodic and working memory, eighteen days after their last ISRIB treatments, the old mice were trained every day for four days to use visual cues to locate a single escape tunnel on a platform with 40 holes. By the fourth day the old mice were finding the tunnel on average 20 seconds faster than the old mice who had never been treated with ISRIB.

The researchers studied the cells of the hippocampus, a part of the brain necessary for learning and memory. When they did, they found that the common markers of aging were largely absent and that the connectivity and electrical responsiveness of the cells were improved.

“The signs of aging diminished overnight,” Rosi explained in the interview. “For the first time we saw that the cognitive decline of old age is not necessarily a permanent loss of capacity or mental resources. Rather, the cells may just get caught up in a cycle of stress. ISRIB seems to break the cycle and re-boot the brain.”

Walter first identified the therapeutic potential of ISRIB in 2013. He and UCSF together hold the patent. In 2015 they licensed ISRIB to Calico.

Follow me on TwitterCheck out my website.

Memory-Boosting Chemical Is Identified in Brains of Mice

UCSF Cell Biologists Find Molecule Targets a Key Biological Pathway

By Jeffrey NorrisFacebook

Memory improved in mice injected with a small, drug-like molecule discovered by UC San Francisco researchers studying how cells respond to biological stress.

The same biochemical pathway the molecule acts on might one day be targeted in humans to improve memory, according to the senior author of the study, Peter Walter, PhD, UCSF professor of biochemistry and biophysics and a Howard Hughes Medical Institute investigator.

Peter Walter, PhD

The discovery of the molecule and the results of the subsequent memory tests in mice were published in eLife, an online scientific open-access journal, on May 28.

In one memory test included in the study, normal mice were able to relocate a submerged platform about three times faster after receiving injections of the potent chemical than mice that received sham injections.

The mice that received the chemical also better remembered cues associated with unpleasant stimuli – the sort of fear conditioning that could help a mouse avoid being preyed upon.

Notably, the findings suggest that despite what would seem to be the importance of having the best biochemical mechanisms to maximize the power of memory, evolution does not seem to have provided them, Walter said.

“It appears that the process of evolution has not optimized memory consolidation; otherwise I don’t think we could have improved upon it the way we did in our study with normal, healthy mice,” Walter said.

Identifying the Chemical that Enhances Memory

The memory-boosting chemical was singled out from among 100,000 chemicals screened at the Small Molecule Discovery Center at UCSF for their potential to perturb a protective biochemical pathway within cells that is activated when cells are unable to keep up with the need to fold proteins into their working forms.

However, UCSF postdoctoral fellow Carmela Sidrauski, PhD, discovered that the chemical acts within the cell beyond the biochemical pathway that activates this unfolded protein response, to more broadly impact what’s known as the integrated stress response. In this response, several biochemical pathways converge on a single molecular lynchpin, a protein called eIF2 alpha.

Scientists have known that, in organisms ranging in complexity from yeast to humans, different kinds of cellular stress – such as a backlog of unfolded proteins, DNA-damaging UV light, a shortage of the amino acid building blocks needed to make protein, viral infection, iron deficiency — trigger different enzymes to act downstream to switch off eIF2 alpha.

“Among other things, the inactivation of eIF2 alpha is a brake on memory consolidation,” perhaps an evolutionary consequence of a cell or organism becoming better able to adapt in other ways, Walter said.

Turning off eIF2 alpha dials down production of most proteins, some of which may be needed for memory formation, Walter said. But eIF2 alpha inactivation also ramps up production of a few key proteins that help cells cope with stress.

Study co-author Nahum Sonenberg, PhD, of McGill University previously linked memory and eIF2 alpha in genetic studies of mice, and his lab group also conducted the memory tests for the current study.

Potential for Human Drug Development

The chemical identified by the UCSF researchers is called ISRIB, which stands for integrated stress response inhibitor. ISRIB counters the effects of eIF2 alpha inactivation inside cells, the researchers found.

“ISRIB shows good pharmacokinetic properties [how a drug is absorbed, distributed and eliminated], readily crosses the blood-brain barrier, and exhibits no overt toxicity in mice, which makes it very useful for studies in mice,” Walter said. These properties also indicate that ISRIB might serve as a good starting point for human drug development, according to Walter.

Walter said he is looking for scientists to collaborate with in new studies of cognition and memory in mouse models of neurodegenerative diseases and aging, using ISRIB or related molecules.

In addition, chemicals such as ISRIB could play a role in fighting cancers, which take advantage of stress responses to fuel their own growth, Walter said. He already is exploring ways to manipulate the unfolded protein response to inhibit tumor growth, based on his earlier discoveries.

At a more basic level, Walter said, he and other scientists can now use ISRIB to learn more about the role of the unfolded protein response and the integrated stress response in disease and normal physiology.

Additional UCSF study authors are Diego Acosta-Alvear, PhD, Punitha Vedantham, PhD, Brian Hearn, PhD, Ciara Gallagher, PhD, Kenny Ang, PhD, Chris Wilson, PhD, Voytek Okreglak, PhD, Byron Hann, MD, PhD, Michelle Arkin, PhD, and Adam Renslo, PhD. Other authors are Han Li, PhD, and Avi Ashkenazi, PhD, from Genentech; and, Karim Nader, PhD, Karine Gamache, and Arkady Khoutorsky, PhD, from McGill University.

The study was funded by the Howard Hughes Medical Institute.

Research Finds ‘Achilles Heel’ for Aggressive Prostate Cancer

Treatment-Resistant Cancers Self-Destruct When Exposed to Experimental Drug

By Nicholas Weiler

Cell image of metastatic human prostate cancer cells, in red, killed by ISRIB.
Metastatic human prostate cancer cells transplanted into a mouse self-destruct (red) when treated with ISRIB, an experimental drug that exposes cancer cells to their full, unhealthy appetite for protein synthesis. Credit: Ruggero Lab / UCSF

UC San Francisco researchers have discovered a promising new line of attack against lethal, treatment-resistant prostate cancer.

Analysis of hundreds of human prostate tumors revealed that the most aggressive cancers depend on a built-in cellular stress response to put a brake on their own hot-wired physiology. Experiments in mice and with human cells showed that blocking this stress response with an experimental drug – previously shown to enhance cognition and restore memory after brain damage in rodents – causes treatment-resistant cancer cells to self-destruct while leaving normal cells unaffected.

Headshot of Davide Ruggero, PhD, the Helen Diller Family Chair in Basic Cancer Research and a professor of urology and cellular and molecular pharmacology at UCSF.
Davide Ruggero, PhD, the Helen Diller Family Chair in Basic Cancer Research and a professor of urology and cellular and molecular pharmacology at UCSF and paper’s senior author. 

The new study was published online May 2 in Science Translational Medicine.

“We have learned that cancer cells become ‘addicted’ to protein synthesis to fuel their need for high-speed growth, but this dependence is also a liability: too much protein synthesis can become toxic,” said senior author Davide Ruggero, PhD, the Helen Diller Family Chair in Basic Cancer Research and a professor of urology and cellular and molecular pharmacology at UCSF. “We have discovered the molecular restraints that let cancer cells keep their addiction under control and showed that if we remove these restraints they quickly burn out under the pressure of their own greed for protein.”

“This is beautiful scientific work that could lead to urgently needed novel treatment strategies for men with very advanced prostate cancer,” added renowned UCSF Health prostate cancer surgeon Peter Carroll, MD, MPH, who is chair of the Department of Urology at UCSF and was a co-author on the new paper.

Peter Carroll, MD, MPH, chair of the Department of Urology at UCSD and co-author on the paper.

Prostate cancer is the second leading cause of cancer death for men in the United States: More than one man in 10 will be diagnosed in his lifetime, and one in 41 will die of the disease, according to data from the American Cancer Society. Tumors that recur or fail to respond to surgery or radiation therapy are typically treated with hormonal therapies that target the cancer’s dependence on testosterone. Unfortunately, most cancers eventually develop resistance to hormone therapy, and become even more aggressive, leading to what is known as “castration-resistant” disease, which is nearly always fatal.

As part of a “growth first” strategy, many cancers contain gene mutations that drive them to produce proteins at such a high rate that they risk triggering cells’ built-in self-destruct mechanisms, according to studies previously conducted by Ruggero and colleagues. But aggressive, treatment-resistant prostate cancers typically contain multiple such mutations, which led Ruggero and his team at the UCSF Helen Diller Family Comprehensive Cancer Center to wonder how such cancers sustain themselves under the pressure of so much protein production.

Deadliest Cancers Throttle Excess Protein Synthesis

To explore this question, Ruggero’s team genetically engineered mice to develop prostate tumors containing a pair of mutations seen in nearly 50 percent of patients with castration-resistant prostate cancer: one that causes overexpression of the cancer-driving MYC gene, and one that disables the tumor suppressor gene PTEN. They were surprised to discover that the highly aggressive cancers associated with these mutations actually had lower rates of protein synthesis compared to milder cancers with only a single mutation.

“I spent six months trying to understand if this was actually occurring, because it’s not at all what we expected,” said Crystal Conn, PhD, a postdoctoral researcher in the Ruggero lab and one of the paper’s two lead authors. But she saw the same effects again and again in experiments in mouse and human cancer cell lines as well as in 3-dimensional “organoid” models of the prostate that could be studied and manipulated in lab dishes.

Conn’s experiments eventually revealed that the combination of MYC and PTEN mutations trigger part of a cellular quality control system called the unfolded protein response (UPR), which reacts to cellular stress by reducing levels of protein synthesis throughout the cell. Specifically, these mutations alter the activity of a protein called eIF2a (eukaryotic translation initiation factor 2a key regulator of protein synthesis, by turning it into an alternate form, P-eIF2a, which tunes down cellular protein production.

Science image of highly aggressive prostate cancers express high levels of a molecule called P-eIF2a (red) that protects the cancer from its own unhealthy appetite for protein synthesis
Highly aggressive prostate cancers in mice express high levels of a molecule called P-eIF2a (red) that protects the cancer from its own unhealthy appetite for protein synthesis. Credit: Ruggero Lab / UCSF

To assess whether levels of P-eIF2a in patient tumors could be used to predict the development of aggressive, treatment-resistant disease, Conn collaborated with Carroll, who holds the Ken and Donna Derr-Chevron Distinguished Professorship in Urology, and Hao Nguyen, MD, PhD, an assistant professor of urology, to examine 422 tumors surgically extracted from UCSF prostate cancer patients. They used a technique called tissue microarray to measure the levels of PTEN, Myc, and P-eIF2a proteins in these tumors, then asked how these biomarkers predicted patient outcomes using 10 years of clinical follow-up data.

They found that P-eIF2a levels were a powerful predictor of worse outcomes in patients with PTEN-mutant tumors: Only 4 percent of such tumors with low P-eIF2a continued to spread following surgery, while 19 percent of patients with high P-eIF2a went on to develop metastases, and many eventually died. In fact, the presence of PTEN mutations and high P-eIF2a levels in prostate tumors outperformed a current standard test (CAPRA-S) used to assess risk of cancer progression following surgery.

ISRIB Selectively Kills Aggressive Prostate Cancers

Next, the researchers examined whether blocking P-eIF2a‘s suppression of protein synthesis might effectively kill aggressive prostate cancers, said Nguyen, who was co–lead author on the new paper. “Once we realized that these cancers are activating part of the UPR to put the brakes on their own protein synthesis, we began to ask what happens to the cancer if you remove the brakes,” he said.

Peter Walter, PhD, Professor Howard Hughes Investigator UCSF School of Medicine Biochemistry and Biophysics
Peter Walter, PhD, Professor of Biochemistry and Biophysics, one of the authors on the paper. 

The researchers collaborated with UCSF biochemist Peter Walter, PhD, whose lab recently identified a molecule called ISRIB that reverses the effects of P-eIF2a activity. (Walter and UCSF neuroscientist Susanna Rosi, PhD, have shown that ISRIB can boost cognition and restore memory after severe brain damage in rodents – likely by restoring the production of proteins needed for learning in injured brain cells.)

Conn tested ISRIB on mice with prostate tumors and in human cancer cell lines and discovered that the drug exposed aggressive cancer cells carrying combined PTEN/MYC mutations to their full drive for protein synthesis, causing them to self-destruct. Intriguingly, she found that the drug had little effect on normal tissue or even on less-aggressive cancers lacking the MYC mutation. In mice, PTEN/MYC prostate tumors began to shrink within 3 weeks of ISRIB treatment, and had not regrown after 6 weeks of treatment, while in contrast, PTEN-only tumors had expanded by 40 percent.

To further investigate the potential use of ISRIB against aggressive human prostate cancer, Nguyen implanted samples of human prostate cancer into mice, a research technique called “patient-derived xenografts” (PDX) that has historically been unsuccessful in studies of prostate cancer.

In one experiment, the researchers transplanted different groups of mice with cells from two tumors extracted from the same prostate cancer patient: one set of cells from the patient’s primary prostate tumor and another from a nearby metastatic colony in the patient’s lymph node. They found that mice implanted with cells from the metastatic sample – which exhibited the expected “aggressive” proteomic profile of high MYC, low PTEN, and high P-eIF2a levels – experienced dramatic tumor shrinkage and extended survival when treated with ISRIB, while mice implanted with cells from the less-aggressive primary prostate tumor experienced only a temporary slowing of tumor growth.

The authors used a third PDX model of metastatic prostate cancer to assess whether blocking the UPR could effectively treat advanced castration-resistant disease: they showed that transplanted tumors, which typically spread and kill mice within 10 days, were significantly reduced and the animals’ lives significantly extended under ISRIB treatment.

“Together these experiments show that blocking P-eIF2α signaling with ISRIB both slows down tumor progression and also kills off the cells that have already progressed or metastasized to become more aggressive,” Conn said. “This is very exciting because finding new treatments for castration-resistant prostate cancer is a pressing and unmet clinical need.”

The researchers hope that this discovery will quickly lead to clinical trials for ISRIB or related drugs for patients with advanced, aggressive prostate cancer. “Most molecules that kill cancer also kill normal cells,” Ruggero said. “But with ISRIB we’ve discovered a beautiful therapeutic window: normal cells are unaffected because they aren’t using this aspect of the UPR to control their protein synthesis but aggressive cancer cells are toast without it.”

“The only side effect we’re aware of,” Conn added, “is that this drug might make you smarter.”

Additional authors on the paper include: Yae Kye, Lingru Xue, Craig M Forester, MD, PhD, Janet E Cowan, Andrew C Hsieh, MD, John T Cunningham, PhD, Charles Truillet, PhD, Michael J Evans, PhD, Byron Hann, MD, PhD, and Peter Walter, PhD, of UCSF; Feven Tameire and Constantinos Koumenis, PhD, of the University of Pennsylvania Perelman School of Medicine; and Christopher P Evans, MD, and Joy C Yang, PhD, of the UC Davis School of Medicine.

The research was supported by the US National Institutes of Health (R01-CA140456, R01-CA154916, and P01-CA165997), the US Department of Defense (W81XWH-15-1-0460), the AUA-SUO-Prostate Cancer Foundation (16YOUN14), the Urology Care Foundation (A130596), the American Cancer Society (PF-14-212-01-RMC), an American Association of Cancer Research (AACR)-Bayer Prostate Cancer Research Fellowship (17-40-44-CONN), the Campini Foundation, the Leukemia and Lymphoma Foundation, the American Cancer Society (130635-RSG-17-005-01-CCE), Calico Life Sciences LLC, the Weill Foundation, the Howard Hughes Medical Institute (HHMI), the UCSF Department of Pediatrics (5K12HDO72222-05), and the Goldberg-Benioff Program in Translational Cancer Biology.

UC San Francisco (UCSF) is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, transitional and population sciences; and a preeminent biomedical research enterprise. It also includes UCSF Health, which comprises three top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children’s Hospitals in San Francisco and Oakland, and other partner and affiliated hospitals and healthcare providers throughout the Bay Area. 

Gene Plays Critical Role in Noise-Induced Deafness

Experimental Drug Prevents Inner-Ear Damage, Protects Hearing

By Nina Bai and Dana Smith

Science images of mouse cochlea in Tmtc4-knockout mice showing hair-cell death.
Upper left: Inner hair cells (orange row at top) and outer hair cells (blue/green array at bottom) in the cochlea of mice lacking the Tmtc4 gene, 10 days after birth. Upper right: Substantial decrease, through cell death, of both types of hair cells, 30 days after birth. Bottom left: 45 days after birth, no hair cells remain. Bottom right: For comparison, outer hair cells in a normal mouse 30 days after birth. Credit: Sherr and Chan labs/UCSF.

In experiments using mice, a team of UC San Francisco researchers has discovered a gene that plays an essential role in noise-induced deafness. Remarkably, by administering an experimental chemical – identified in a separate UCSF lab in 2013 – that acts on the pathway linking this gene to hearing loss, they found that they could prevent noise-induced deafness in the mice, a condition that affects tens of millions of adults and about 17 percent of teens in the U.S.

The researchers said a similar drug to the one used in their study might one day be used as a hearing-protection regimen before working in a noisy environment or going to a loud concert. They’re also looking at whether it could be taken shortly after exposure to loud noise to protect hearing, such as when soldiers are exposed to explosions on the battlefield.

Whether of environmental or genetic origin, hearing loss is almost always caused by damage to sensory “hair cells” in the cochlea, which detect sound waves and transmit auditory information to the brain. Unlike many types of cells in the body, if hair cells die, they cannot regenerate.

“It doesn’t take very long for hair cells to die and for the cochlea to basically become a scar – the whole structure of the cochlea changes,” said Dylan Chan, MD, PhD, an assistant professor of otolaryngology at UCSF and co-senior author of the new paper. “To restore hearing would not only require getting hair cells to regenerate, but also reproducing this finely tuned mechanical structure. The better option is to try and prevent the death of hair cells in the first place.”

As reported in the Oct. 15, 2018, issue of The Journal of Clinical Investigation, researchers led by Elliott Sherr, MD, professor of neurology and of pediatrics at UCSF, were interested in a gene called Tmtc4 for its potential role in brain development. When the team deleted the gene in mouse embryos, they were surprised to discover that the mice became almost completely deaf by one month after birth.

“The observation that these mice were going deaf was a fortuitous one, so we took it and ran with it and really landed right on the biology,” said Sherr. “A lot of times when you do experiments you get hints that you’re heading in the right direction, but literally every experiment we did pointed us in the same direction. We were able to go from observation to mechanism to treatment in one window of time, which was really exciting.”

The Tmtc4 protein normally plays a role in the endoplasmic reticulum (ER), a structure inside the cell that helps regulate the majority of protein production. Working with Chan, Sherr’s group found that the loss of Tmtc4 in cochlear hair cells distorted the delicate balance of calcium that ordinarily exists between the ER and the rest of the cell and triggered the unfolded protein response (UPR) – a quality control system that causes a cell to self-destruct if it’s producing faulty (and perhaps dangerous) proteins. The UPR triggered hair-cell suicide, ultimately leading to total deafness.

Because the mice could hear normally after they were born, the researchers realized that they weren’t dealing some form of congenital deafness. Instead, they suspected that the rapid hearing loss observed in Tmtc4-deficient mice was due to a heightened sensitivity to normal sounds. To test this hypothesis, the researchers exposed normal mice to loud noises and found that this triggered hair-cell death triggered by the UPR, just as was seen in the mice lacking Tmtc4.

“No one had shown that noise-induced hearing loss involved the unfolded protein response,” said Chan. “It really opens up a lot of potential for identifying different therapeutic options and exploring how targeting the UPR could be effective for lots of kinds of hearing loss that we really don’t have any treatments for.”

To avert noise-induced hearing loss in the mice, the scientists needed to somehow block the UPR and prevent hair cells from self-destructing. Fortunately, they were right down the hall from Peter Walter, PhD, a professor of biochemistry and biophysics at UCSF whose lab identified a drug in 2013 that does precisely that. The compound, known as ISRIB (for Integrated Stress Response Inhibitor) inhibits part of the UPR; it has been shown to reverse memory failure caused by traumatic brain injury in mice and to kill aggressive prostate cancer cells.

Giving the mice ISRIB before they were exposed to loud noises prevented hair cell damage and noise-induced hearing loss, and Sherr says the researchers are now looking to see if the treatment would be useful to prevent other types of hearing loss, including age-related hearing loss.

“People who become deaf as they get older become very isolated. There’s a lot of associated depression and an increase in the risk of developing dementia, so there are lots of good reasons for us to try to prevent hearing loss later in life.”

Authors: Additional authors on the paper include Jiang Li, MD, PhD, Omar Akil, PhD, Stephanie Rouse, Conor McLaughlin, MD, and Ian Matthews, of UCSF, and Lawrence Lustig, MD, of Columbia University.

Funding: This work was supported in part by the National Institute of Neurological Disorders and Stroke (2R01NS058721), the National Institute on Deafness and Other Communication Disorders (R03DC015082), and the National Center for Advancing Translational Sciences (UL1TR001872).

Conflicts: Sherr and Chan are founders and shareholders in Jacaranda Biosciences. Sherr is listed as an inventor on a published patent application, Novel Methods of Treating Hearing Loss (PCT/US2016/058348).

UC San Francisco (UCSF) is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, translational and population sciences; and a preeminent biomedical research enterprise. It also includes UCSF Health, which comprises three top-ranked hospitals – UCSF Medical Center and UCSF Benioff Children’s Hospitals in San Francisco and Oakland – as well as Langley Porter Psychiatric Hospital and Clinics, UCSF Benioff Children’s Physicians and the UCSF Faculty Practice. UCSF Health has affiliations with hospitals and health organizations throughout the Bay Area. UCSF faculty also provide all physician care at the public Zuckerberg San Francisco General Hospital and Trauma Center, and the SF VA Medical Center. The UCSF Fresno Medical Education Program is a major branch of the University of California, San Francisco’s School of Medicine.

 

 

Drug Reverses Age-Related Mental Decline Within Days

Rapid Rejuvenation of Mental Faculties in Aged Mice Implicates Reversible Physiological ‘Blockage’ Behind Age-Related Cognitive Losses

By Nicholas Weiler

 

A cryo-electron microscope rendering of an ISRIB molecule. Image by the Adam Frost lab

 

Just a few doses of an experimental drug can reverse age-related declines in memory and mental flexibility in mice, according to a new study by UC San Francisco scientists. The drug, called ISRIB, has already been shown in laboratory studies to restore memory function months after traumatic brain injury (TBI), reverse cognitive impairments in Down Syndrome, prevent noise-related hearing loss, fight certain types of prostate cancer, and even enhance cognition in healthy animals.

In the new study, published Dec. 1, 2020, in the open-access journal eLife, researchers showed rapid restoration of youthful cognitive abilities in aged mice, accompanied by a rejuvenation of brain and immune cells that could help explain improvements in brain function.

“ISRIB’s extremely rapid effects show for the first time that a significant component of age-related cognitive losses may be caused by a kind of reversible physiological “blockage” rather than more permanent degradation,” said Susanna Rosi, PhD, Lewis and Ruth Cozen Chair II and professor in the departments of Neurological Surgery and of Physical Therapy and Rehabilitation Science.

“The data suggest that the aged brain has not permanently lost essential cognitive capacities, as was commonly assumed, but rather that these cognitive resources are still there but have been somehow blocked, trapped by a vicious cycle of cellular stress,” added Peter Walter, PhD, a professor in the UCSF Department of Biochemistry and Biophysics and a Howard Hughes Medical Institute investigator. “Our work with ISRIB demonstrates a way to break that cycle and restore cognitive abilities that had become walled off over time.”

Could Rebooting Cellular Protein Production Hold the Key to Aging and Other Diseases?

Walter has won numerous scientific awards, including the BreakthroughLasker and Shaw prizes, for his decades-long studies of cellular stress responses. ISRIB, discovered in 2013 in Walter’s lab, works by rebooting cells’ protein production machinery after it gets throttled by one of these stress responses – a cellular quality control mechanism called the integrated stress response (ISR; ISRIB stands for ISR InhiBitor).

Peter Walter, PhD. Photo by Elisabeth Fall

 

The ISR normally detects problems with protein production in a cell — a potential sign of viral infection or cancer-promoting gene mutations — and responds by putting the brakes on cell’s protein-synthesis machinery. This safety mechanism is critical for weeding out misbehaving cells, but if stuck in the on position in a tissue like the brain, it can lead to serious problems, as cells lose the ability to perform their normal activities, Walter and colleagues have found.

In particular, recent animal studies by Walter and Rosi, made possible by early philanthropic support from The Rogers Family Foundation, have implicated chronic ISR activation in the persistent cognitive and behavioral deficits seen in patients after TBI, by showing that, in mice, brief ISRIB treatment can reboot the ISR and restore normal brain function almost overnight.

The cognitive deficits in TBI patients are often likened to premature aging, which led Rosi and Walter to wonder if the ISR could also underlie purely age-related cognitive decline. Aging is well known to compromise cellular protein production across the body, as life’s many insults pile up and stressors like chronic inflammation wear away at cells, potentially leading to widespread activation of the ISR.

“We’ve seen how ISRIB restores cognition in animals with traumatic brain injury, which in many ways is like a sped-up version of age-related cognitive decline,” said Rosi, who is director of neurocognitive research in the UCSF Brain and Spinal Injury Center and a member of the UCSF Weill Institute for Neurosciences. “It may seem like a crazy idea, but asking whether the drug could reverse symptoms of aging itself was just a logical next step.”

Improves Cognition, Boosts Neuron and Immune Cell Function

In the new study, researchers led by Rosi lab postdoc Karen Krukowski, PhD, trained aged animals to escape from a watery maze by finding a hidden platform, a task that is typically hard for older animals to learn. But animals who received small daily doses of ISRIB during the three-day training process were able to accomplish the task as well as youthful mice, much better than animals of the same age who didn’t receive the drug.

The researchers then tested how long this cognitive rejuvenation lasted and whether it could generalize to other cognitive skills. Several weeks after the initial ISRIB treatment, they trained the same mice to find their way out of a maze whose exit changed daily – a test of mental flexibility for aged mice who, like humans, tend to get increasingly stuck in their ways. The mice who had received brief ISRIB treatment three weeks before still performed at youthful levels, while untreated mice continued to struggle.

To understand how ISRIB might be improving brain function, the researchers studied the activity and anatomy of cells in the hippocampus, a brain region with a key role in learning and memory, just one day after giving animals a single dose of ISRIB. They found that common signatures of neuronal aging disappeared literally overnight: neurons’ electrical activity became more sprightly and responsive to stimulation, and cells showed more robust connectivity with cells around them while also showing an ability to form stable connections with one another usually only seen in younger mice.

Susanna Rosi, PhD. Photo by Susan Merrell

 

The researchers are continuing to study exactly how the ISR disrupts cognition in aging and other conditions and to understand how long ISRIB’s cognitive benefits may last. Among other puzzles raised by the new findings is the discovery that ISRIB also alters the function of the immune system’s T cells, which also are prone to age-related dysfunction. The findings suggest another path by which the drug could be improving cognition in aged animals, and could have implications for diseases from Alzheimer’s to diabetes that have been linked to heightened inflammation caused by an aging immune system.

“This was very exciting to me because we know that aging has a profound and persistent effect on T cells and that these changes can affect brain function in the hippocampus,” said Rosi. “At the moment, this is just an interesting observation, but it gives us a very exciting set of biological puzzles to solve.”

Broad Effects Exemplify ‘Serendipity’ of Basic Research

Rosi and Walter were introduced by neuroscientist Regis Kelly, PhD, executive director of the University of California’s QB3 biotech innovation hub, following Walter’s 2013 study showing that the drug seemed to instantly enhance cognitive abilities in healthy mice. To Rosi, the results from that study implied some walled-off cognitive potential in the brain that the molecule was somehow unlocking, and she wondered if this extra cognitive boost might benefit patients with neurological damage from traumatic brain injury.

 

ISRIB’S WIDE-RANGING IMPLICATIONS

Chronic ISR activation and resulting blockage of cellular protein production may play a role in a surprisingly wide array of neurological conditions. Here are the conditions where there is already evidence that the ISR plays a role, and which could potentially be treated with an ISR-resetting agent like ISRIB.

  • Frontotemporal Dementia
  • Alzheimer’s Disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Age-related Cognitive Decline
  • Multiple Sclerosis
  • Traumatic Brain Injury
  • Parkinson’s Disease
  • Down Syndrome
  • Vanishing White Matter Disorder
  • Prion Disease

See a recent review by Walter and colleague Mauro Costa-Mattioli of Baylor College of Medicine in Houston.

 

The labs joined forces to study the question in mice, and were astounded by what they found. ISRIB didn’t just make up for some of the cognitive deficits in mice with traumatic brain injury – it erased them. “This had never been seen before,” Rosi said. “The mantra in the field was that brain damage is permanent – irreversible. How could a single treatment with a small molecule make them disappear overnight?”

Further studies demonstrated that neurons throughout the brains of animals with traumatic brain injury are thoroughly jammed up by the ISR. Using ISRIB to release those brakes lets brain cells immediately get back to their normal business. More recently, studies in animals with very mild repetitive brain injury – akin to pro athletes who experience many mild concussions over many years – showed that ISRIB could reverse increased risk-taking behavior associated with damage to self-control circuits in the frontal cortex.

“Added to this, Karen’s new results in aging mice are just amazing. It’s not often that you find a drug candidate that shows so much potential and promise,” Walter added. “This project also shows the power of the UCSF community – Susanna and I didn’t know each other and were living in different worlds until Regis Kelly brought us together, making this powerful connection that neither of us had realized before.”

“Amazing breakthroughs like this need more than the brilliance and experimental skills of Susanna and Peter,” said Kelly. “They also need donors like the Rogers Family Foundation willing to bridge the gap between great basic research and products that could be highly beneficial to society.”

ISRIB has been licensed by Calico, a South San Francisco, Calif. company exploring the biology of aging, and the idea of targeting the ISR to treat disease has been picked up by many other pharmaceutical companies, Walter says.

One might think that interfering with the ISR, a critical cellular safety mechanism, would be sure to have serious side effects, but so far in all their studies, the researchers have observed none. This is likely due to two factors, Walter says. First, it takes just a few doses of ISRIB to reset unhealthy, chronic ISR activation back to a healthier state, after which it can still respond normally to problems in individual cells. Second, ISRIB has virtually no effect when applied to cells actively employing the ISR in its most powerful form – against an aggressive viral infection, for example.

Naturally, both of these factors make the molecule much less likely to have negative side effects – and more attractive as a potential therapeutic. “It almost seems too good to be true, but with ISRIB we seem to have hit a sweet spot for manipulating the ISR with an ideal therapeutic window,” Walter said.

Authors: Other authors on the study were Amber Nolan, Elma S. Frias, Morgane Boone, Katherine Grue, Maria-Serena Paladini, and Edward Elizarraras of UCSF; and Gonzalo Ureta, Luz Delgado and Sebastian Bernales of Fundación Ciencia & Vida in Santiago, Chile. Bernales is also an employee of Praxis Biotech, LLC.

Funding: The study was supported by continued generous support of the Rogers Family Foundation, as well as the UCSF Weill Innovation Award, the U.S. National Institutes of Health (NIH R01AG056770), National Institute on Aging (NIA F32AG054126); National Center for Advancing Translational Sciences (NCATS TL1 TR001871); ANID Project AFB 170004; National Institute of Neurological Disorders and Stroke (NINDS K08NS114170) and the Howard Hughes Medical Institute (HHMI).

Disclosures: Gonzalo Ureta works at Fundacion Ciencia & Vida and receives partial funding from Praxis Biotech. Sebastian Bernales is an employee of Praxis Biotech. Peter Walter is an inventor on U.S. Patent 9708247 held by the Regents of the University of California that describes ISRIB and its analogs. Rights to the invention have been licensed by UCSF to Calico.

The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes UCSF Health, which comprises three top-ranked hospitals, as well as affiliations throughout the Bay Area.

Drug Reverses Memory Failure Caused by Traumatic Brain Injury

After Treatment, Brain-Injured Mice Perform as Well as Normal Mice on Memory Tests

By Pete Farley

In an unprecedented finding, UC San Francisco scientists used an experimental drug to completely reverse severe learning and memory impairments caused by traumatic brain injury (TBI) in mice. Surprisingly, the drug fully restored the ability to learn and remember in the brain-injured mice even when the animals were first treated as much as a month after injury.

The latter results are particularly striking, as most research on brain injury and stroke has suggested that treatments must be initiated as quickly as possible to preserve normal function.

The researchers said the new study offers a promising new avenue for the treatment of TBI in humans, which affects nearly two million individuals annually in the U.S. – one every 21 seconds. In addition to causing serious cognitive deficits, which can be short-lived or permanent, TBI is also a leading risk factor for the development of Alzheimer’s disease and other forms of dementia. But dozens of seemingly promising treatments have failed in clinical trials, and no approved therapies are currently available.

Two Types of Brain Injuries

The drug used in the new research, known as ISRIB (pronounced “iz-rib”), was discovered in 2013 in the laboratory of Peter Walter, PhD, professor of biochemistry and biophysics at UCSF and co-senior author of the new study, which will be published online during the week of July 10, 2017, in Proceedings of the National Academy of Sciences. ISRIB was licensed in 2015 to Calico, a company involved in understanding the biology that controls the human lifespan.

Peter Walter
Peter Walter, PhD

“This is extraordinarily exciting,” said Walter, also a Howard Hughes Medical Institute (HHMI) investigator. “We think that ISRIB may uncover an untapped reservoir in the brain that allows damaged memory circuits to be repaired.”

In the new research, scientists in the laboratory of co-senior author Susanna Rosi, PhD, professor of physical therapy and rehabilitation sciences and of neurological surgery at UCSF, tested whether ISRIB – which had previously been shown by Walter and colleagues to enhance memory in normal mice – could improve the ability to learn and form memories in mice with two different types of brain injury, each of which are known to degrade learning and memory in humans.

“In general, animals with these injuries never learn well again,” said Rosi, a member of the UCSF Weill Institute for Neurosciences and director of neurocognitive research at UCSF’s Brain and Spinal Injury Center, located at partner institution Zuckerberg San Francisco General Hospital. “So it’s remarkable that ISRIB could restore the ability to form new memories even when we delayed giving the drug for four weeks after the injury. This has not been considered possible.”

Localized brain injuries called focal contusions can affect spatial memory, which helps both mice and humans navigate through the world and complete necessary everyday tasks. Concussive brain injuries – which cause diffuse trauma to the whole brain – can degrade “working memory,” a temporary storage system that is critical for reasoning and decision-making. 

Restoration of Ability to Learn Persisted

To test ISRIB’s potential effects after focal injury, both normal and brain-injured mice were placed in a “radial-arm water maze,” in which they had to learn the location of a platform hidden under milky water in one of eight arms of the maze.

Susanna Rosi
Susanna Rosi, PhD

Mice are averse to swimming, and after a brief training period normal mice improve steadily on this task, eventually finding the platform quite quickly after being placed into the maze. But brain-injured mice continue to make errors – swimming into incorrect arms of the maze in search of the platform – with no sign of improvement, long after training.

In the new research, however, when brain-injured mice were given three injections of ISRIB beginning four weeks after injury (the injections were spaced one day apart), their performance in the maze was indistinguishable from that of normal mice, and the restoration of their ability to learn persisted for a week after the last injection.

Given ISRIB’s pharmacology, Rosi said, the persistence of its effects is intriguing, and indicates that it may induce some durable change in the brain. “ISRIB’s half-life is less than a day, and when the mice demonstrated intact memory ability a week after receiving it, we know there is only the most miniscule trace of the drug left in their bodies.”

To test whether ISRIB could restore working memory after concussive brain injury, members of Rosi’s lab used a modified Barnes maze, which resembles a tabletop perforated with 40 holes; one of these holes leads to an escape tunnel, which normal mice efficiently learn to locate.

As with the radial-arm water maze, brain-injured mice usually perform poorly on this test, but when the mice with concussive injuries received ISRIB injections – in this case, four daily injections, beginning two weeks after injury – they again performed as well as their normal counterparts.

Blocks Part of the Integrated Stress Response

ISRIB works by blocking a part of a protective cellular system known as the Integrated Stress Response, or ISR (the drug’s name means “Integrated Stress Response InhiBitor”). When cells are injured or under stress from infection or a lack of nutrients, the ISR slows down translation, the process by which the genetic instructions encoded within DNA are converted into functional proteins. By binding to a central cellular player involved in translation, ISRIB allows stressed cells to override the ISR, with protein translation proceeding apace.

the ISRIB molecule
The ISRIB drug was discovered in 2013 in the laboratory of Peter Walter, PhD.

In addition to the memory experiments described in the new paper, Walter and Rosi report experiments with brain slices showing that both focal and concussive injury activate the ISR in the hippocampus, a brain region that is crucial for memory, and that the ISR remains active for 28 days after the injury. Applying ISRIB to the slices not only dampened the effects of the ISR, but restored a process known as long-term potentiation, or LTP, a persistent strengthening of neural connections that is believed to be crucial to the formation of new memories.

Walter, who has won both the Albert Lasker Basic Medical Research Award and the Shaw Prize, two of the most prestigious prizes in biomedicine, for groundbreaking work on a system closely related to the ISR, believes that ISRIB may reverse memory loss in damaged nerve cells by restoring proper control of the synthesis of proteins that are essential to LTP and other cellular bases of memory. But he and Rosi “are still in a discovery phase” in understanding ISRIB’s mechanism of action, Walter said. “We are exploring. We are going into the unknown.”

And as startling as the new results are, Rosi said, the drug’s effectiveness must undergo many more studies before it would be a candidate for clinical trials to treat brain-injured patients, work that she and Walter are undertaking with an Innovation Award from the UCSF Weill Institute for Neurosciences, which they shared in October 2016 for their work on ISRIB and TBI.

“We need to do much more research,” Rosi said, “but I have high hopes that this drug can bring back lost memory capacity to our patients who have suffered brain injuries.”

In addition to Walter and Rosi, UCSF authors of the new study include Austin Chou, a graduate student in the Department of Neurological Surgery; Karen Krukowski, PhD, a postdoctoral scholar; and Timothy Jopson, a former research associate. They were joined by Ping Jun Zhu, MD, and Mauro Costa-Mattioli, PhD, both in the Department of Neuroscience at Baylor College of Medicine.

The research was supported by the Rogers Family Foundation, the National Institutes of Health, and HHMI.

UC San Francisco (UCSF) is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, translational and population sciences; and a preeminent biomedical research enterprise. It also includes UCSF Health, which comprises three top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children’s Hospitals in San Francisco and Oakland, and other partner and affiliated hospitals and healthcare providers throughout the Bay Area.

LiquidPiston Rotary Engine

 

LIQUIDPISTON ENGINES
ARE TAKING OFF

10X MORE POWER, 30% MORE EFFICIENT

WATCH US FLY

ENGINES FOR VEHICLES AND POWER GENERATION.

LEARN MORE

Featured on Discovery Channel

ENGINES DESIGNED FOR APPLICATIONS WHERE LESS IS MORE

 

Less weight, space, vibration, noise, fuel consumption… More power. Building on over 15 years of R&D, LiquidPiston provides a power solution that can scale to address the needs of the $400B internal combustion engine market and is a key enabler for emerging mobility technologies including electric cars, urban aircraft, and drones.

The company is focusing on military and aerospace markets, whose propulsion and power generation segments represent large application opportunities for LiquidPiston. The company also plans to enter industrial and commercial, marine, UAV, urban mobility, and automotive markets.

 
 
 
 
 
Slide 1 of 5.
 
 
 

TECHNOLOGY

 

LiquidPiston’s rotary engines are the first disruption to engine technology in over a century. These engines are not Wankel engines; they are uniquely configured to adopt the company’s patented thermodynamic cycle and its associated efficiency and low-noise benefits. LiquidPiston’s X Engine improves virtually all parameters – efficiency, weight, size, vibration, and noise.

VIEW BROCHURE

HIGH EFFICIENCY HYBRID CYCLE (HEHC)

 

LiquidPiston’s HEHC is a patented thermodynamic cycle that combines the advantages of Diesel, Otto and Atkinson thermodynamic cycles, resulting in up to 30% improved efficiency.

HOW IT WORKS

 

A simple, efficient and elegant system, the X Engine only has a few moving parts, including the rotor (the primary work-producing component) and an eccentric shaft. Aside from ancillary parts such as injectors, fuel pumps and oil pumps, there are no other additional moving parts.

X-MINI SPARK-IGNITED
(MULTI FUEL) ENGINE

READ MORE
 

COMPRESSION-IGNITED  DIESEL ENGINES

READ MORE

 

HOW IT’S MADE

 

LiquidPiston was featured on How It’s Made, a documentary series from the Science Channel that offers viewers a look behind the scenes at how everyday things are manufactured. Watch our episode from Season 31 below for an in-depth look at the makings of LiquidPiston rotary engines.

TECHNICAL
PAPERS

READ MORE

 

FREQUENTLY ASKED
QUESTIONS

READ MORE

 

ABOUT US

 

Based in Bloomfield, CT, LiquidPiston develops compact, powerful, quiet, efficient, lowvibration, multi-fuel capable combustion engines that are scalable from 1HP to over 1000 HP.

LiquidPiston maintains state-of-the-art laboratory facilities dedicated to developing and testing engines and supporting components

LiquidPiston has built two fully equipped dynamometer/test cells and laboratory test setups with instrumentation.

LiquidPiston also has a machine shop with CNC machining and assembly capabilities.

NEWS

9.15.2020

LIQUIDPISTON EARNS ARMY GRANT FOR NEXT GEN DRONE ENGINE

9.1.2018

INSIDE OUT-THINKING: DOSSIER ON LIQUIDPISTON

6.14.2016

HOW A 4-POUND ENGINE CAN REPLACE A 40-POUND ENGINE

7.13.2020

BLOOMFIELD’S LIQUIDPISTON DOUBLES HQ SIZE, HIRES NEW TECHNOLOGY SPECIALIST

MORE MEDIA COVERAGE

9.15.2020

NEW APPLICATIONS FROM LIQUIDPISTON ENABLE AIRCRAFT ELECTRIFICATION TO IMPROVE DRONE AND ROTORCRAFT FLIGHT DURATION AND FUEL EFFICIENCY

8.7.2018

LIQUIDPISTON PRESENTS SMALL COMPRESSION-IGNITED ROTARY ENGINE AT THE GROUND VEHICLE SYSTEMS ENGINEERING AND TECHNOLOGY SYMPOSIUM (GVSETS)

MORE PRESS RELEASES

ARE YOU AN INVESTOR IN LIQUIDPISTON, OR INTERESTED IN OPEN INVESTMENT OPPORTUNITIES?

 
INVESTOR RELATIONS

CAREERS

 

Can an engineer change the world? We’re looking to expand our team.
Please check our open positions.

VIEW OPEN POSITIONS

Will a New Glass Battery Hammer the Last Nail on the Coffin of Oil?

Will a New Glass Battery Accelerate the End of Oil?

New low-cost, nonflammable, high-capacity, rapid-charging solid-state battery could pose threat to the internal combustion engine

By Mark Anderson
John Goodenough, coinventor of the lithium-ion battery, heads a team of researchers developing the technology that could one day supplant it.
Photo: Cockrell School of Engineering
John Goodenough, coinventor of the lithium-ion battery, heads a team of researchers developing the technology that could one day supplant it.
Advertisement

Electric car purchases have been on the rise lately, posting an estimated 60 percent growth rate last year. They’re poised for rapid adoption by 2022, when EVs are projected to cost the same as internal combustion cars. However, these estimates all presume the incumbent lithium-ion battery remains the go-to EV power source. So, when researchers this week at the University of Texas at Austin unveiled a new, promising lithium- or sodium-glass battery technology, it threatened to accelerate even rosy projections for battery-powered cars.

“I think we have the possibility of doing what we’ve been trying to do for the last 20 years,” says John Goodenough, coinventor of the now ubiquitous lithium-ion battery and emeritus professor at the Cockrell School of Engineering at the University of Texas, Austin. “That is, to get an electric car that will be competitive in cost and convenience with the internal combustion engine.” Goodenough added that this new battery technology could also store intermittent solar and wind power on the electric grid.

Yet, the world has seen alleged game-changing battery breakthroughs come to naught before. In 2014, for instance, Japanese researchers offered up a cotton-based (!) new battery design that was touted as “energy dense, reliable, safe, and sustainable.” And if the cotton battery is still going to change the world, its promoters could certainly use a new wave of press and media releases, as an Internet search on their technology today produces links that are no more current than 2014-2015 vintage.

So, on whose authority might one claim a glass battery could be any different?

For starters, Donald Sadoway’s. Sadoway, a preeminent battery researcher and MIT materials science and engineering professor, says, “When John Goodenough makes an announcement, I pay attention. He’s tops in the field and really a fantastic scientist. So, his pronouncements are worth listening to.”

Goodenough himself says that when he first coinvented the lithium-ion battery in the 1980s, almost no one in the battery or consumer electronics industries took the innovation seriously. It was only Japanese labs and companies like Sony that first began to explore the world we all today inhabit—with lithium-ions powering nearly every portable device in the marketplace, as well as electric vehicles and even next-generation airliners.

In other words, who better than Goodenough to cocreate the technology that could one day supplant his mighty lithium-ion battery?

The new battery technology uses a form of glass, doped with reactive “alkali” metals like lithium or sodium, as the battery’s electrolyte (the medium between cathode and electrode that ions travel across when the battery charges and discharges). As outlined in a research paper and recent patent filing (of which Goodenough, 94, says more are forthcoming), the lithium- or sodium-doped glass electrolyte offers a new medium for novel battery chemistry and physics.

They find, for instance, that the lithium- or sodium-glass battery has three times the energy storage capacity of a comparable lithium-ion battery. But its electrolyte is neither flammable nor volatile, and it doesn’t appear to build up the spiky “dendrites” that have plagued lithium-ions as they charge and discharge repeatedly and can ultimately short out, causing battery fires. So, if the glass batteries can be scaled up commercially, which remains uncertain in this still-proof-of-concept-phase research, the frightening phenomenon of flaming or exploding laptops, smartphones, or EVs could be a thing of the past.

Moreover, says lithium-glass battery codeveloper Maria Helena Braga, a visiting research fellow at UT Austin and engineering professor at the University of Porto in Portugal, the glass battery charges in “minutes rather than hours.” This, she says, is because the lithium- or sodium-doped glass endows the battery with a far greater capacity to store energy in the electric field. So, the battery can, in this sense, behave a little more like a lightning-fast supercapacitor. (In technical terms, the battery’s glass electrolyte endows it with a higher so-called dielectric constant than the volatile organic liquid electrolyte in a lithium-ion battery.)

Moreover, Braga says, early tests of their technology suggest it’s also capable of perhaps thousands of charge-discharge cycles, and could perform well in both extremely cold and hot weather. (Initial estimates place its operating range between below -20º C and 60º C.) And if they can switch the battery’s ionic messenger atom from lithium to sodium, the researchers could even source the batteries more reliably and sustainably. Rather than turning to controversial mining operations in a few South American countries for lithium, they’d be able to source sodium in essentially limitless supply from the world’s seawater.

Sadoway says he’s eager to learn more about the technology as it continues to be developed. In particular, he’s paying attention not so much to how quickly the battery charges but how well it can retain its energy. “The issue is not can you do something at a high charge rate,” he says. “My big question is about capacity fade and service lifetime.”

But, Sadoway adds, perhaps the chief innovation behind Goodenough and Braga’s technology is the possibility that they’ve solved the flaming and exploding battery problem.

“Addressing the [battery] safety issue is, I think, a giant step forward,” he says. “People have been talking about solid-state electrolytes for 20 years. But I can’t point to a commercial product yet…. If he can give us an electrolyte that is devoid of these flammable, organic solvents, that’s salutary in my opinion.”

If Goodenough, Braga, and collaborators can ramp up their technology, there would clearly be plenty of upsides. Goodenough says the team’s anode and electrolyte are more or less ready for prime time. But they’re still figuring out if and how they can make a cathode that will bring the promise of their technology to the commercial marketplace.

“The next step is to verify that the cathode problem is solved,” Goodenough says. “And when we do [that] we can scale up to large-scale cells. So far, we’ve made jelly-roll cells, and it looks like they’re working fairly well. So I’m fairly optimistic we’ll get there. But the development is going to be with the battery manufacturers. I don’t want to do development. I don’t want to be going into business. I’m 94. I don’t need the money.”

 

The Energywise Newsletter

Monthly newsletter on latest news & opinion for the power & energy industry, green technology, and conservation.

About the Energywise blog

IEEE Spectrum’s energy, power, and green tech blog, featuring news and analysis about the future of energy, climate, and the smart grid.

 

New World Record in Solar Cell Efficiency with perovskite/silicon tandem solar cell

Scientists Just Set a New World Record in Solar Cell Efficiency

 
14 DECEMBER 2020

Improving the efficiency of solar cells can make a huge difference to the amount of energy produced from the same surface area and the same amount of sunshine, and another world record has been beaten in the push for better yields.

Researchers have now hit an efficiency of 29.15 percent in the perovskite/silicon tandem solar cell category, which is just one of several different types of cells. There are currently a variety of different technologies in use to convert solar energy into electricity.

For this type of panel, the long-term target of more than 30 percent is now tantalisingly within reach. The latest lab tests edge ahead of the maximum 28 percent efficiency that perovskite/silicon cells have managed up to this point.

solar 2The layers of the tandem solar cell. (Eike Köhnen/HZB)

“Tandem solar cells that pair silicon with a metal halide perovskite are a promising option for surpassing the single-cell efficiency limit,” write the researchers in their published paper. “We report a monolithic perovskite/silicon tandem with a certified power conversion efficiency of 29.15 percent.”

Perovskite and silicon have actually been developed separately as semiconductor materials for solar panel use: silicon cells have been around for longer, and are currently the standard in solar farms around the world.

Perovskite is the up and coming new challenger, which scientists think could eventually eclipse silicon in terms of usefulness.

That’s why scientists have long been experimenting with different perovskite compound combinations and adding other materials – silicon, in this case. The so-called tandem cell uses two semiconductors that can capture two different parts of the light spectrum, extending beyond infrared light (captured by silicon) into visible light too (captured by the perovskite compounds).

More good news is that putting perovskite and silicon together doesn’t substantially add to the cost of making the panels. Keeping the price down is important for getting solar technology rolled out as far and as quickly as possible.

In this new research, the 29.15 percent efficiency record was managed with a 1 cm x 1 cm (0.4 inch x 0.4 inch) panel, so some serious scaling up will be required. The team says that should be possible, however. After 300 hours of simulated use, the tandem cell retained 95 percent of its original efficiency, which is another promising sign.

The new record was actually first reported earlier this year, though the peer-reviewed paper detailing the feat has just been published. The scientists used specially tweaked layer compositions for both connecting the electrode layer and keeping the two types of cell together in order to reach their new record.

It’s another moment to celebrate, but the scientists aren’t stopping: previous research suggests that tandem solar cell technology should be able to reach efficiency rates of well above 30 percent, and the team says “initial ideas for this are already under discussion”.

The research has been published in Science.

Best Linux for Gaming

Best Linux Distributions Crafted Specifically for Gaming

Long gone are the times when gaming on Linux was next to impossible. In fact, gaming on Linux has grown quite stable in recent years.

Although there are hundreds of Linux distros, all with different ideals and for various purposes, distros made for the sole purpose of gaming are not very common. But, of course, there are some really great options available. We are going to list the best Linux gaming distributions today.

These distros are equipped with various drivers, emulators, and software for a convenient gaming experience, so you can just install them and get the gaming going.

Do note that most of the major Linux distributions support thousands of games with the help of Steam (and Steam Play).

Best Linux Gaming OS

Just for clarification, this list of the best gaming Linux distributions is no particular order.

1. Steam OS

Steam OS, developed by Valve Corp. (the creator of Steam), is one of the most popular gaming distros. Steam OS is designed for running games from the Steam Store.

Primis Player Placeholder

 
 
 

Steam OS
Steam OS

Base: Debian 8 (codenamed Debian Jessie)
Desktop Environment: GNOME, optimized for easy access with Keyboard and Joystick.
Package Format: deb

Steam OS supports various graphics cards and joysticks/gamepads. If, by chance, a driver for your hardware is not included out-of-box, you can always manually set that up.

Hardware Requirements

  • Processor: Intel or AMD 64-bit capable processor
  • Memory: 4GB or more RAM
  • Hard Drive: 200GB or larger disk
  • Video Card: NVIDIA graphics card / AMD graphics card (RADEON 8500 and later) / Intel graphics
  • Additional: USB port for installation, UEFI Firmware (recommended)

Pros

  • Soothing User Interface
  • Supports various graphics cards
  • Compatible with various joysticks/gamepads
  • Huge collection of games from built-in Steam game store

Cons

  • High-end hardware requirements
  • Only Steam games available out-of-box

If you are a hardcore Steam fan and own a machine that meets the requirements, Steam OS is without a doubt for you.

2. batocera.linux

batocera.linux is an impressive Linux distro for retro games. You can play retro games from Atari, Super Nintendo, SEGA, Dreamcast, some GameBoy Advance games, and a lot more. However, you need to own the games in order to play them.

You do not need to install the OS by partitioning your hard drive, you just need a USB stick and you can boot directly from it to play the games you own. It also comes with Kodia Media Center integrated, so that you can switch to watching movies when you get bored of games.

Pros

  • Supports Nvidia graphics cards (you need to enable this feature by referring the forum)
  • Does not require modifications to your hard disk
  • Raspberry Pi and Odroid supported
  • Kodi Media Center integrated

Cons

  • Only retro games
  • Limited software support for Raspberry Pi and Odroid

3. Linux Console

Linux Console is a very lightweight, youth-focused Linux distro to install on your PC, gaming console, or servers to play games. It does support a lot of addictive games, like hedgewars and pinball.

You can also install games like Cuphead, by following the official instructions on their website. In addition, you can use it via a Live USB stick or through VMware/VirtualBox.

Pros

  • Tailored for children
  • Actively developed to also support office software, graphics software, emulators and more.

Cons

  • Not a platform for a hardcore gamer

4. Game Drift Linux

Game Drift Linux is optimized to give the best possible gaming experience on Linux. It provides out-of-box support for Linux and popular Windows games.

Game Drift Linux
Game Drift Linux

Base: Ubuntu
Desktop Environment: MATE
Package Format: deb

Game Drift has its own Game Store filled with various open-source games, as well as commercial high quality Linux games. More games are being added regularly. The Game Store supports one-click installation.

The distro takes advantages of CrossOver technology for running Windows games. You can play more than 1200 Windows games directly within Game Drift. You will also be able to run various other Windows software with CrossOver.

Hardware Requirements (Recommended)

  • Processor: 1-2 GHz processor (32 or 64 bit)
  • Memory: 1-2 GB memory
  • Hard Drive: 4 GB hard disk drive for Game Drift Linux (excluding games)
  • Video Card: ATI, Nvidia or Intel graphics adapter
  • Additional: LAN/Internet

Pros

  • Dedicated Game Store
  • Windows games supported

Cons

  • CrossOver is not free (you’ll need to buy an activation key)

If you want Windows games support and can afford to spend some money buying CrossOver, Game Drift Linux is a good choice.

5. Lakka OS

Lakka OS is completely different from the distros we have discussed so far. This is a lightweight Linux distro that transforms a computer into full-blown game console.

Lakka OS
Lakka OS

Base: OpenELEC
Desktop Environment: RetroArch

Lakka OS is able to emulate a wide variety of consoles. It brings all these console emulators under the gorgeous front end of RetroArch.

All the emulators are compiled with the best optimizations possible and so Lakka OS runs the games more smoothly than the normal emulators. Most games will require very few hardware resource, except for the Playstation or Xbox games.

The key features of Lakka OS are multiplayer, savestates, shaders, netplay, rewind, and support for wireless joypads.

Pros

  • Totally lightweight
  • Beautiful user interface
  • All in one console emulator
  • Various hardware supported
  • Automatic joypad recognition
  • Various useful features for gaming

Cons

  • No support for Linux, Steam, or Windows games

If you are a hardcore console gamer and have a machine you want to dedicate, Lakka OS is for you without any doubt.

6. Fedora Games Spin

Fedora Games spin is the perfect example of Fedora’s ability to run games.

Fedora
Fedora

Base: Fedora
Desktop Environment: Xfce
Package Format: RPM

Fedora Games Spin comes with thousands of Linux games. Quoting the official site:

The included games span several genres, from first-person shooters to real-time and turn-based strategy games to puzzle games.

None of Steam client, Wine, or PlayOnLinux are installed by default. If you want Steam and Windows games support, you need to manually install those via the package manager. Some preinstalled games also need additional data to be downloaded before playing.

Pros

  • Thousand of Linux games preinstalled
  • Stable, fast, and light

Cons

  • No out-of-box support for Steam or Windows games
  • Proprietary drivers are not preinstalled
  • Not for hardcore gamers

Though this distro is not the very best for gaming, if you are a Fedora lover you might give this one a try.

7. Ubuntu GamePack

Ubuntu GamePack is a gaming distro that provides a guarantee to lunch about six thousand Linux and Windows games. It was developed with the intention to fill the gap in game availability between Linux and Windows.

Ubuntu GamePack
Ubuntu GamePack

Base: Ubuntu
Desktop Environment: Unity
Package Format: deb

Ubuntu GamePack does not include any games out-of-box. Rather, it opens the door for running Linux, Steam, Windows, and various consoles’ games on your machine.

Steam client, Lutris, Wine, and PlayOnLinux come preinstalled with Ubuntu GamePack. Lutris is an open gaming platform for managing console, Linux, Steam, and Windows games.

It also supports Adobe Flash and Oracle Java, so playing online games will not be a problem.

Ubuntu GamePack also provides a dedicated repository with a collection of hundreds of games.

Pros

  • Pre-installed Lutris
  • Compatible for playing online games
  • Linux, Steam, Windows, and console games supported

Cons

  • Might seem a bit slow

8. mGAMe

mGAMe (previously known as Manjaro Gaming) is a distro designed for gamers with the awesomeness of Manjaro. If you are a regular It’s F.O.S.S. reader, you know about this one already. We introduced this Gaming distro a while back. In case you missed it, here’s the article: Manjaro Gaming.

mGAMe
mGAMe

Base: Manjaro
Desktop Environment: Xfce

mGAMe automatically installs the necessary drivers for popular graphics cards. It also provides various tweaks for optimal gaming experience.

mGAMe comes with various open source software for things often needed by gamers, like video editing, game video recording and streaming, chatting, taking screenshots, etc.

A long list of console emulators comes preinstalled with mGAMe. For running Windows games, Wine and PlayOnLinux are included. But if you want to play Steam games, you have to manually install the Steam client, which is a big deal in Arch Linux based distributions as Steam is not officially supported.

Pros

  • Preinstalled tools for gamers
  • Wide range of console emulators included

Cons

  • Not suitable for hardcore gamers

mGAMe is a relatively new addition to this genre of Linux distro. But if you are a Manjaro fan, you can try it out.

9. Sparky Linux GameOver Edition

Sparky Linux Gameover Edition is another great distro for gaming.

Sparky Linux - Gameover Edition
Sparky Linux – Gameover Edition

Base: Debian
Desktop Environment: LXDE
Package Format: deb

Sparky Linux GameOver Edition comes with a special tool called APTus Gamer. It features an easy way to install various consoles, emulators, and other tools for gamers. A long list of emulators is available through APTus Gamer.

A large number of Linux open source games come preinstalled with this distro. Moreover, it also comes with Steam client. Also, for Windows Games, Wine and PlayOnLinux are bundled with Sparky Linux GameOver Edition.

It also provides a utility to help with installing proprietary drivers, and an easy way to install multimedia codecs.

Pros

  • Steam games supported
  • Windows games supported via Wine and PlayOnLinux
  • Sparky APTus Gamer tool
  • Stable release

Cons

  • None?

If you want a stable Linux distro for gaming that supports a wide range of games from different platforms, just try this one out.

Play Linux [Discontinued]

Conclusion

That’s all we’ve got for the best Linux system for gaming. The next time someone asks, “which Linux operating system is best for gaming?” don’t forget to share this article with them. 🙂

Have you tried any of these distros? Which one of these particularly caught you eye? Let us know!

 

 

 

 
 

 

About Munif Tanjim

Munif is studying Electronics & Telecommunication Engineering. He loves Open Source and uses Ubuntu as his primary OS. Technology aside, Munif is a TV Series freak and sometimes tries to do some creative writing.

Bionic Eye Tech Learns Its ABCs

Bionic Eye Tech Learns Its ABCs

An experiment stimulates monkeys’ brains to generate shape perceptions

 
Bionic Eye Tech Learns Its ABCs
Credit: Alamy

Jens Naumann was 17 when an accident sent a fragment of metal from a railway line flying into his left eye. Three years later, a metal sliver from a snowmobile clutch destroyed his right eye, plunging him into total darkness. Naumann’s book Search for Paradise recounts his desperate quest back to the light, primarily as biomedical engineer William Dobelle’s “patient alpha.” In the 1970s, Dobelle had shown that electrically stimulating visual brain areas (the visual cortex) caused people to perceive spots of light, or “phosphenes.”

 
 
 

The engineer’s goal was to develop a “bionic eye.” The apparatus would consist of a head-mounted camera that feeds video to a computer processor, which would then send electrical signals to electrodes implanted in the visual cortex, generating visual perceptions. Naumann became Dobelle’s most famous patient after traveling to Portugal for surgery in 2002; the FDA had banned the procedure in the U.S. as not having been proven to be safe. His anecdotal accounts of perceiving crude outlines remained the only evidence researchers had that perception of shapes was possible using such a device, because data from these procedures were never published. The device degraded after a few months, and Naumann’s newfound visual world faded away, but he has continued to campaign through the years to move the technology forward.

A more sophisticated version that moves the technology closer to routine practical use in people has now been built and tested in monkeys. A team led by neuroscientist Pieter Roelfsema, of the Netherlands Institute for Neuroscience, has demonstrated perception of position, orientation, motion, and letter shapes, in two sighted monkeys. The study, published December 3 in Science “is a technical tour de force,” says neurosurgeon Daniel Yoshor, who was not involved but co-wrote an accompanying commentary. The device needs further development before it is ready for use in humans, but the work brings nearer the dream of restoring vision to people who have none. The approach is the only possible treatment for people without functioning cells in the eye—a group that includes some glaucoma and diabetes patients and those who have experienced a physical trauma.

In the new study, the team used 16 arrays, each a grid of 64 electrodes, for a total of 1024 electrodes. “We tiled a large fraction of the surface of the cortex, thereby creating an interface with a large fraction of this map of visual space,” Roelfsema says. The visual cortex has a property known as “retinotopy,” which means that visual space physically maps onto areas of the cortex, allowing researchers to generate phosphenes at specific points in space. A series of experiments showed that the monkeys could identify the position of individual phosphenes, the orientation of lines consisting of two phosphenes, and the direction of motion implied by stimulating two sequentially. Finally, monkeys who had been trained to recognize letters seemed to be able to identify letters generated from between eight and 15 phosphenes. The phosphenes were generated without using cameras by directly stimulating electrodes, and the monkeys indicated responses using eye movements.

Other groups are working on the same problem, and one is already testing devices in humans. A California company, Second Sight, is developing a system called Orion in six blind people in an FDA-approved clinical trial. Like Dobelle’s system, Orion uses electrodes that sit on the brain’s surface that avoids the tissue damage and inflammation that arises when using “penetrating” implants, which results in a loss of performance over time. A disadvantage of this method is that currents required are relatively high, limiting the number of electrodes that can be used safely. “You don’t want to induce epilepsy,” Roelfsema says. The new study from the Netherlands group used penetrating electrodes, which require less current. “We used thin needles, so we can activate just a few cells, with relatively mild currents, a hundred times smaller than you need with a surface electrode,” Roelfsema says. Most significantly, the new device has far higher resolution. Where the new system has 1,024 electrodes, the Orion implant has 60, limiting recipients to detecting areas of dark and light.

The vision this device might generate would be crude compared to the richness of natural vision, but still provide a substantial benefit. “When you start at nothing, 10, 20 percent is game-changing,” says Neena Haider of Harvard Medical School, who was not involved in the work. “It gives you a window into how to navigate the world.” But obstacles remain before this technology sees human use. First, implants must be wireless—and other groups are making efforts to develop wireless brain implants. Next steps also need to measure the physiological consequences of penetrating implants, Haider says. “What cellular responses are happening in the brain?” she asks, regarding both acute and long-term effects. “Biocompatibility” remains an issue, but solutions may be at hand. “We’re working with groups that develop thin, flexible electrodes,” pushed into the brain using rods that are then retracted, Roelfsema says. “First impressions are these new materials are very stable, but there’s still work to do.”

Better understanding how the brain processes visual information will also help. “There’s a hardware challenge and a software challenge,” Yoshor says. “Sometimes people neglect the software element, which is how we stimulate the brain.” Yoshor is one of two neurosurgeons who have implanted Orion in patients, and he and colleagues recently published a study  exploring its capabilities. “It’s easy to make patients see spots,” Yoshor says. “But when we try to combine them, like stadium lights, it’s much harder to get patients to perceive a coherent form.” The research team wondered whether exploiting the brain’s propensity for detecting changes in stimulation might help. “If we stimulated six electrodes simultaneously, patients saw inconsistent blobs,” Yoshor says. “But when we swept across the brain, patients were immediately able to detect visual forms or letters.”

The processing performed by the visual system is incredibly complex, but deeper understanding of this processing, together with more sophisticated stimulation technologies, will continue to advance these devices. Yoshor likens the problem to playing music. “It’s like the difference between playing a chord and banging a piano with your fists,” he says. “If you input information crudely, you produce a cacophony; it has to be done in a way that’s musical.”